Insider Selling: BioNTech (NASDAQ:BNTX) CEO Sells $3,139,840.00 in Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 32,000 shares of the stock in a transaction that occurred on Wednesday, September 30th. The shares were sold at an average price of $98.12, for a total value of $3,139,840.00. Following the completion of the sale, the chief executive officer directly owned 214,209 shares of the company’s stock, valued at $21,018,187.08. The trade was a 13.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Monday, September 28th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $98.47, for a total transaction of $3,347,980.00.
• On Friday, September 25th, Ugur Sahin sold 27,000 shares of BioNTech stock. The shares were sold at an average price of $98.69, for a total value of $2,664,630.00.
• On Thursday, September 24th, Ugur Sahin sold 39,000 shares of BioNTech stock. The shares were sold at an average price of $98.99, for a total value of $3,860,610.00.
• On Wednesday, September 23rd, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $99.40, for a total transaction of $2,982,000.00.
• On Tuesday, September 22nd, Ugur Sahin sold 46,000 shares of BioNTech stock. The shares were sold at an average price of $100.72, for a total transaction of $4,633,120.00.
• On Monday, September 21st, Ugur Sahin sold 33,000 shares of BioNTech stock. The shares were sold at an average price of $97.81, for a total value of $3,227,730.00.
• On Friday, September 18th, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $96.22, for a total transaction of $2,886,600.00.
• On Thursday, September 17th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $98.60, for a total transaction of $3,352,400.00.
• On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The shares were sold at an average price of $96.09, for a total value of $1,441,350.00.
• On Tuesday, September 15th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $96.49, for a total transaction of $3,280,660.00.

BioNTech Price Performance

BNTX traded down $0.27 during midday trading on Wednesday, reaching $98.30. 807,438 shares of the company’s stock were exchanged, compared to its average volume of 1,091,041. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80. BioNTech SE Sponsored ADR has a 1-year low of $79.52 and a 1-year high of $124.00. The stock has a market capitalization of $24.86 billion, a PE ratio of -12.55 and a beta of 1.29. The business’s 50-day moving average price is $98.43 and its 200 day moving average price is $94.90.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The company had revenue of $122.31 million for the quarter, compared to analyst estimates of $180.18 million. During the same quarter last year, the company posted ($1.60) EPS. BioNTech’s quarterly revenue was down 59.5% compared to the same quarter last year. As a group, equities analysts anticipate that BioNTech SE Sponsored ADR will post -6.37 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on BNTX shares. UBS Group reissued a “buy” rating on shares of BioNTech in a research note on Wednesday, September 16th. Canaccord Genuity Group reduced their price objective on BioNTech from $142.00 to $136.00 and set a “buy” rating on the stock in a research note on Monday, August 31st. Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a research note on Monday, July 6th. Morgan Stanley lowered their price objective on BioNTech from $126.00 to $119.00 and set an “overweight” rating for the company in a research note on Wednesday, July 8th. Finally, Wall Street Zen downgraded shares of BioNTech from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, BioNTech presently has a consensus rating of “Moderate Buy” and a consensus price target of $126.00.

Institutional Trading of BioNTech

Several large investors have recently added to or reduced their stakes in the business. Flossbach Von Storch SE acquired a new position in BioNTech during the 2nd quarter valued at about $207,142,000. First Trust Advisors LP increased its stake in BioNTech by 116.0% in the 1st quarter. First Trust Advisors LP now owns 839,991 shares of the company’s stock worth $74,658,000 after purchasing an additional 451,124 shares in the last quarter. Assenagon Asset Management S.A. purchased a new position in shares of BioNTech in the second quarter worth approximately $39,385,000. SEB Asset Management AB purchased a new position in BioNTech during the 1st quarter worth approximately $17,804,000. Finally, Bank of America Corp DE raised its position in BioNTech by 22.6% during the first quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock valued at $80,261,000 after buying an additional 166,432 shares during the period. 15.52% of the stock is currently owned by institutional investors and hedge funds.

About BioNTech

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company’s research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.